Alx Oncology Holdings, Inc. (ALXO) has disclosed a new risk, in the Share Price & Shareholder Rights category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alx Oncology Holdings, Inc. faces a significant business risk due to potential delisting from the Nasdaq Global Select Market, which could severely impact its stock liquidity and ability to raise funds. The company has been notified of non-compliance with Nasdaq’s minimum bid price requirement, as its stock has consistently closed below $1.00 per share since March 10, 2025. With a compliance deadline set for October 20, 2025, Alx Oncology must ensure its stock price meets the minimum requirement to avoid delisting. Failure to regain compliance could lead to further declines in stock price and liquidity, posing a substantial challenge for the company and its shareholders.
The average ALXO stock price target is $2.25, implying 316.67% upside potential.
To learn more about Alx Oncology Holdings, Inc.’s risk factors, click here.